<DOC>
	<DOC>NCT00483717</DOC>
	<brief_summary>The study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.</brief_summary>
	<brief_title>Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine</brief_title>
	<detailed_description>Evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Diagnosis of migraine with or without aura (IHS criteria 1.1 and 1.2.1); Onset of migraine prior to age 50; 28 moderate to severe migraine headaches per month Subjects receiving any investigational drug within 30 days before study entry; More than 15 headache days per month; Known allergy or hypersensitivity to ketorolac and/or excipients; Allergy to aspirin or other NSAIDs; Currently receiving other NSAIDs or aspirin; Medical history that would preclude NSAID use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Ketorolac</keyword>
</DOC>